{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:15:34Z","timestamp":1790727334989,"version":"4.1.0"},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,2,27]]},"DOI":"10.18632\/oncotarget.24191","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T12:30:00Z","timestamp":1515760200000},"page":"12971-12981","source":"Crossref","is-referenced-by-count":21,"title":["CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma"],"prefix":"10.18632","volume":"9","author":[{"given":"Julia D.S.","family":"Hanauer","sequence":"first","affiliation":[{"name":"Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Rengstl","sequence":"additional","affiliation":[{"name":"Dr. Senckenberg Institute of Pathology, Goethe-University Frankfurt, Frankfurt am Main, Germany"},{"name":"Current address: BioNTech Cell and Gene Therapies GmbH, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Kleinl\u00fctzum","sequence":"additional","affiliation":[{"name":"Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Reul","sequence":"additional","affiliation":[{"name":"Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anett","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Friedel","sequence":"additional","affiliation":[{"name":"Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene C.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Newrzela","sequence":"additional","affiliation":[{"name":"Dr. Senckenberg Institute of Pathology, Goethe-University Frankfurt, Frankfurt am Main, Germany"},{"name":"Current address: BioNTech Cell and Gene Therapies GmbH, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin-Leo","family":"Hansmann","sequence":"additional","affiliation":[{"name":"Dr. Senckenberg Institute of Pathology, Goethe-University Frankfurt, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Buchholz","sequence":"additional","affiliation":[{"name":"Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Muik","sequence":"additional","affiliation":[{"name":"Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany"},{"name":"Current address: BioNTech RNA Pharmaceuticals GmbH, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin\u2019s lymphoma","volume":"9","author":"K\u00fcppers","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/jcp.55.3.162","article-title":"Hodgkin\u2019s lymphoma: the pathologist\u2019s viewpoint","volume":"55","author":"Stein","year":"2002","journal-title":"J Clin Pathol"},{"key":"3","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1309\/NB3947K383DJ0LQ2","article-title":"The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T\/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression","volume":"128","author":"Hsi","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"4","first-page":"CD007110","article-title":"Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma","volume":"4","author":"Skoetz","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA Approval Summary. Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma","volume":"22","author":"Pazdur","year":"2017","journal-title":"Oncologist"},{"key":"6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40265-017-0705-5","article-title":"Brentuximab Vedotin. A Review in CD30-Positive Hodgkin Lymphoma","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"7","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Younes","year":"2016","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ebiom.2016.06.046","article-title":"Oncolytic Viruses: Therapeutics With an Identity Crisis","volume":"9","author":"Bell","year":"2016","journal-title":"EBioMedicine"},{"key":"9","doi-asserted-by":"crossref","first-page":"e1115641","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Galluzzi","year":"2016","journal-title":"Oncoimmunology"},{"key":"10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/v8030063","article-title":"Retargeting Strategies for Oncolytic Herpes Simplex Viruses","volume":"8","author":"Gatta","year":"2016","journal-title":"Viruses"},{"key":"11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-61779-340-0_11","article-title":"Oncolytic measles virus retargeting by ligand display","volume":"797","author":"Galanis","year":"2012","journal-title":"Methods Mol. Biol"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Msaouel, Opyrchal, Dispenzieri, Peng, Federspiel, Russell, Galanis. Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets. 2017 Feb 22. [Epub ahead of print].","DOI":"10.2174\/1568009617666170222125035"},{"key":"13","doi-asserted-by":"crossref","first-page":"E294","DOI":"10.3390\/v8100294","article-title":"Measles to the Rescue: A Review of Oncolytic Measles Virus","volume":"8","author":"Fielding","year":"2016","journal-title":"Viruses"},{"key":"14","doi-asserted-by":"crossref","first-page":"8332","DOI":"10.1128\/JVI.03823-13","article-title":"Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus\/measles virus hybrid VSV-FH a growth advantage over measles virus","volume":"88","author":"Peng","year":"2014","journal-title":"J Virol"},{"key":"15","first-page":"10","article-title":"Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus. Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective","volume":"7","author":"Buchholz","year":"2017","journal-title":"Front Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/protein\/gzv005","article-title":"Receptor-targeted lentiviral vectors are exceptionally sensitive toward the biophysical properties of the displayed single-chain Fv","volume":"28","author":"Schneider","year":"2015","journal-title":"Protein Eng Des Sel"},{"key":"17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nbt1060","article-title":"Rescue and propagation of fully retargeted oncolytic measles viruses","volume":"23","author":"Russell","year":"2005","journal-title":"Nat Biotech"},{"key":"18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/ni1285","article-title":"Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma","volume":"7","author":"Stein","year":"2006","journal-title":"Nat Immunol"},{"key":"19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Okoye","year":"2011","journal-title":"Nature"},{"key":"20","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2012-05-428896","article-title":"Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma","volume":"120","author":"Hansmann","year":"2012","journal-title":"Blood"},{"key":"21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/17474086.2017.1270202","article-title":"Diagnostic, prognostic and therapeutic role of CD30 in lymphoma","volume":"10","author":"Mehta","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/smim.1998.0156","article-title":"CD30: expression and function in health and disease","volume":"10","author":"Watanabe","year":"1998","journal-title":"Semin Immunol"},{"key":"23","first-page":"nri888","article-title":"Viruses and interferon. A fight for supremacy","volume":"2","author":"Gale","year":"2002","journal-title":"Nature Reviews Immunology"},{"key":"24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Durbin","year":"2003","journal-title":"Cancer Cell"},{"key":"25","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","article-title":"Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma","volume":"31","author":"Lowe","year":"2017","journal-title":"Leukemia"},{"key":"26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1089\/scd.2015.0386","article-title":"CD30 Receptor-Targeted Lentiviral Vectors for Human Induced Pluripotent Stem Cell-Specific Gene Modification","volume":"25","author":"Schneider","year":"2016","journal-title":"Stem Cells and Development"},{"key":"27","doi-asserted-by":"crossref","first-page":"15012","DOI":"10.1038\/mto.2015.12","article-title":"Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity","volume":"2","author":"Peng","year":"2015","journal-title":"Mol Ther Oncolytics"},{"key":"28","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/srep02375","article-title":"Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy","volume":"3","author":"Peng","year":"2013","journal-title":"Sci Rep"},{"key":"29","doi-asserted-by":"crossref","first-page":"20729","DOI":"10.1073\/pnas.1312509110","article-title":"Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed-Sternberg cells","volume":"110","author":"Hansmann","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"30","doi-asserted-by":"crossref","first-page":"e1160186","DOI":"10.1080\/2162402X.2016.1160186","article-title":"Tumor-infiltrating HLA-matched CD4(+) T cells retargeted against Hodgkin and Reed-Sternberg cells","volume":"5","author":"Hartmann","year":"2016","journal-title":"Oncoimmunology"},{"key":"31","doi-asserted-by":"publisher","first-page":"30523","DOI":"10.18632\/oncotarget.8864","article-title":"CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin,","volume":"7","author":"von Bergwelt-Baildon","year":"2016","journal-title":"Oncotarget"},{"key":"32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.critrevonc.2017.02.021","article-title":"Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature","volume":"113","author":"Anwer","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"33","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1099\/vir.0.046672-0","article-title":"Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer","volume":"93","author":"Grdzelishvili","year":"2012","journal-title":"Journal of General Virology"},{"key":"34","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1158\/0008-5472.CAN-13-3306","article-title":"Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency","volume":"74","author":"Miletic","year":"2014","journal-title":"Cancer Res"},{"key":"35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.biomaterials.2017.07.032","article-title":"Covalent coupling of high-affinity ligands to the surface of viral vector particles by protein trans-splicing mediates cell type-specific gene transfer","volume":"144","author":"Buchholz","year":"2017","journal-title":"Biomaterials"},{"key":"36","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Rooney","year":"2017","journal-title":"J Clin Invest"},{"key":"37","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1073\/pnas.91.6.2161","article-title":"Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus","volume":"91","author":"Oldstone","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"38","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/35022579","article-title":"SLAM (CDw150) is a cellular receptor for measles virus","volume":"406","author":"Yanagi","year":"2000","journal-title":"Nature"},{"key":"39","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1158\/0008-5472.CAN-12-2221","article-title":"Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus","volume":"73","author":"Buchholz","year":"2013","journal-title":"Cancer Res"},{"key":"40","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1128\/JVI.02389-05","article-title":"RNA Polymerase II-Controlled Expression of Antigenomic RNA Enhances the Rescue Efficacies of Two Different Members of the Mononegavirales Independently of the Site of Viral Genome Replication","volume":"80","author":"Schneider","year":"2006","journal-title":"J Virol"},{"key":"41","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1099\/vir.0.023978-0","article-title":"Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity","volume":"91","author":"Zimmer","year":"2010","journal-title":"J Gen Virol"},{"key":"42","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jim.2012.06.005","article-title":"Area under the curve as a tool to measure kinetics of tumor growth in experimental animals","volume":"382","author":"Srivastava","year":"2012","journal-title":"J Immunol Methods"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T17:40:20Z","timestamp":1594834820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":42,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018,2,27]]}},"alternative-id":["24191","29560124"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.24191","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,12]]}}}